Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Celltrion Secures Seventh Consecutive Brazilian Government Tender for Herzuma

Celltrion has strengthened its position in Brazil's biopharmaceutical market after securing another major government procurement contract for Herzuma, its biosimilar treatment for breast and gastric cancer. The latest award marks the company's seventh consecutive win in Brazil's federal government tender since 2020, reinforcing its position as a leading supplier of trastuzumab in the…

Celltrion, a South Korean biopharmaceutical company, has secured its seventh consecutive Brazilian government tender for its biosimilar treatment, Herzuma. This marks a significant milestone in the company's expansion within Brazil's biopharmaceutical market, which is predominantly public, accounting for approximately 80% of the overall market.

The latest contract, spanning until the end of 2027, will see Celltrion exclusively supply around 1 million vials of Herzuma, representing roughly 80% of Brazil's public-sector trastuzumab market. This steady stream of government contracts, coupled with the company's strategic manufacturing and distribution capabilities, has helped Celltrion establish itself as a leading supplier of trastuzumab in Brazil.

The company's success in securing these tenders has been attributed to its direct-sales strategy, tailored to Brazil's healthcare procurement structure, and its strong relationships with key government stakeholders and healthcare professionals. Additionally, Celltrion is actively pursuing further growth in Brazil's private healthcare market through the introduction of new products such as Omlyclo and Idensel t.

Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at koreaittimes.com →

More in Finance & Markets

SK hynix’s Nvidia Revenue Nears 35 Trillion Won, Doubling in a Year

SK hynix generated nearly 35 trillion won, or approximately $26.17 billion, in revenue from a customer widely believed to be Nvidia, its largest client, during the first three quarters of this year.

  • SK hynix reported 35 trillion won ($26.17B) in Nvidia revenue Q3, doubling from last year.
  • U.S. market drove growth with 147.74 trillion won, 62.5% of total revenue.
  • China revenue reached 56.14 trillion won, 23.7% of total, up from previous year.

More from Tuesday 17 November →